Flash Therapeutics
Developer of a biologically derived virus‑like particle RNA delivery platform for research and therapeutic applications. Focus areas include multi‑RNA packaging and transient in vitro and in vivo expression, support for preclinical studies and clinical translation (GMP scale‑up and first‑in‑human study planned for 2025), and provision of custom batch production, licensing and technology‑transfer support.
Industries
Nr. of Employees
small (1-50)
Flash Therapeutics
Products
Biologically derived RNA‑competent virus‑like particles (research and clinical batches)
Particles produced in human producer cells that encapsulate biologically transcribed RNAs for multi‑cargo transient delivery; supplied as R&D grade or scaled toward GMP drug product.
Biologically derived RNA‑competent virus‑like particles (research and clinical batches)
Particles produced in human producer cells that encapsulate biologically transcribed RNAs for multi‑cargo transient delivery; supplied as R&D grade or scaled toward GMP drug product.
Services
Manufacture of custom research batches carrying client‑specified RNA sequences for ex vivo and preclinical applications; premade reporter batches also available.
Licensing agreements spanning R&D to clinical/commercial use and structured technology transfer to qualified CDMOs to enable GMP production and clinical supply.
Scientific guidance for molecular design, preclinical experimental design, and clinical translation of RNA delivery projects.
Manufacture of custom research batches carrying client‑specified RNA sequences for ex vivo and preclinical applications; premade reporter batches also available.
Licensing agreements spanning R&D to clinical/commercial use and structured technology transfer to qualified CDMOs to enable GMP production and clinical supply.
Scientific guidance for molecular design, preclinical experimental design, and clinical translation of RNA delivery projects.
Expertise Areas
- RNA delivery platform development
- Co‑delivery of multiple RNA cargos for gene editing and expression
- Preclinical in vivo and ex vivo model development for RNA therapeutics
- Cell engineering for difficult‑to‑transduce primary and stem cells
Key Technologies
- Virus‑like particle (VLP) RNA delivery
- Multi‑cargo RNA packaging
- Transient mRNA expression systems
- Delivery of CRISPR/Cas and base‑editing systems
News & Updates
Company participation at the I4ID congress in Lyon, Nov 13–14, 2025.
Company attendance at BIO‑EUROPE partnering conference in Vienna, Austria, Nov 3–5, 2025.
Company participation at RNA Horizons meeting in Palermo, Italy, Oct 29–31, 2025.
Company attendance and presentation at ESGCT Congress in Seville, Spain, Oct 7–10, 2025.
Company attendance at BIOSPAIN congress in Barcelona, Spain, Oct 7–9, 2025.
Company attendance at NETIB congress in Bordeaux, France, Oct 2–3, 2025.
Company participation at the I4ID congress in Lyon, Nov 13–14, 2025.
Company attendance at BIO‑EUROPE partnering conference in Vienna, Austria, Nov 3–5, 2025.
Company participation at RNA Horizons meeting in Palermo, Italy, Oct 29–31, 2025.
Company attendance and presentation at ESGCT Congress in Seville, Spain, Oct 7–10, 2025.
Company attendance at BIOSPAIN congress in Barcelona, Spain, Oct 7–9, 2025.
Company attendance at NETIB congress in Bordeaux, France, Oct 2–3, 2025.